Gail Nunlee-Bland, MD
Pediatric Endocrinology · Washington, DCNPI 1497788400
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 341 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,154, 2.1 times the $1,007 reported in 2019.
Across 341 payments — averaging $28.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$2K
- Lilly USA, LLC$1K
- Sanofi-aventis U.S. LLC$905
- Boehringer Ingelheim$633
- Novo Nordisk$628
- Abbott$596
- plus $4K from 31 others
Across 16 payments — averaging $9346.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$150K
What the payments were for
- Food & beverage$9,50199%
- Education$150%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 59 | $1,563 |
| Lilly USA, LLC | 44 | $1,011 |
| Sanofi-aventis U.S. LLC | 37 | $905 |
| Boehringer Ingelheim | 27 | $633 |
| Novo Nordisk | 23 | $628 |
| Abbott | 15 | $596 |
| Insulet Corporation | 13 | $523 |
| Dexcom, Inc. | 12 | $519 |
| Tandem Diabetes Care, Inc. | 10 | $436 |
| Xeris Pharmaceuticals, Inc. | 14 | $314 |
| Bayer | 11 | $249 |
| AstraZeneca(2 entities) | 11 | $248 |
| Amgen(2 entities) | 5 | $232 |
| Tolmar, Inc. | 7 | $205 |
| BETA Bionics, Inc. | 5 | $197 |
| Cequr Corporation | 2 | $183 |
| Ascendis Pharma Endocrinology Inc | 4 | $171 |
| Mannkind Corporation | 5 | $133 |
| Medtronic | 5 | $115 |
| Shire North American Group Inc | 6 | $96 |
| Antares Pharma, Inc. | 3 | $70 |
| Madrigal Pharmaceuticals | 2 | $70 |
| Ultragenyx Pharmaceutical Inc. | 3 | $69 |
| Recordati_rare_diseases_inc. | 3 | $60 |
| Soleno Therapeutics, Inc. | 2 | $53 |
| Phadia US Inc. | 1 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Averitas Pharma Inc. | 1 | $28 |
| Biomarin Pharmaceutical Inc. | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Halozyme Inc | 1 | $25 |
| Chiasma, Inc. | 1 | $21 |
| AbbVie | 1 | $19 |
| Companion Medical, Inc. | 1 | $18 |
| Ascensia Diabetes Care US Inc. | 1 | $17 |
| Kerecis Limited | 1 | $15 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$305
- FREESTYLE LIBRE 3$294
- Omnipod$283
- t:slim X2 Insulin Pump with Control-IQ$228
- DEXCOM G6 TRANSMITTER$189
- TEPEZZA$147
- TZIELD$129
- Ozempic$124
- Korlym$116
- DEXCOM G7 GSS (161)$115
- DEXCOM STELO GLUCOSE BIOSENSOR$115
- CeQur Simplicity$110
- RYBELSUS$103
- iLet Insulin Infusion Kit Inset$102
- iLet Insulin Infusion Kit Contact Detach$102
How this compares
$9,576 in reported general payments places this provider in the 65th percentile of 20 pediatric endocrinology providers in District of Columbia.
See all pediatric endocrinology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 68 | $73,339 |
| TrulicityDulaglutide | 45 | $55,508 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $33,915 |
| JardianceEmpagliflozin | 28 | $21,467 |
| MounjaroTirzepatide | 11 | $14,151 |
| JanuviaSitagliptin Phosphate | 12 | $9,237 |
| Novolog FlexpenInsulin Aspart | 15 | $3,488 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 20 | $2,157 |
| Insulin Lispro Protamine MixInsulin Lispro Protamin/Lispro | 11 | $1,767 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,353 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 15 | $1,038 |
| Levothyroxine Sodium | 47 | $449 |
| Metformin Hcl | 50 | $329 |
| Atorvastatin Calcium | 29 | $217 |
| Glipizide ErGlipizide | 11 | $148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $628 | $73,33968 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,011 | $69,65856 claims |
| Boehringer IngelheimJardiance | $633 | $21,46728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 20 pediatric endocrinology providers in District of Columbia.
Other pediatric endocrinology in Washington
- Shideh MajidiWashington$88K
- Fran CogenWashington$63K
- Nadia MerchantWashington$49K
- Abby MeyersWashington$22K
- Roopa Kanakatti ShankarWashington$18K
- Doris EstradaWashington$10K
- Paul KaplowitzWashington$7K
- Alison BoyceWashington$6K
- Jody GrundmanWashington$4K
- Nicolas CuttrissWashington$406
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.